# Plain Language Summary of H.R. 5850

This bill attempts to reverse changes that the Food and Drug Administration made in January 2023 regarding how mifepristone (the medication used in medication abortion) can be prescribed and distributed. Specifically, the FDA had loosened some of the restrictions around this drug, making it easier for patients to access it through mail delivery and allowing more types of healthcare providers to prescribe it. This bill would undo those changes and restore the stricter rules that were in place before.

The bill does two main things. First, it officially cancels the FDA's January 2023 modifications, meaning the old, more restrictive rules would go back into effect. Second, it prohibits the federal government from spending any money to enforce or implement rules similar to what the FDA tried to do. This means the government couldn't use federal funds to support easier access to mifepristone through mail or through a wider range of providers, even if it wanted to.

In practical terms, if this bill became law, it would likely make mifepristone harder to obtain. Patients would probably need to visit a clinic in person rather than receive the medication by mail, and fewer types of doctors would be able to prescribe it. This would particularly affect people in rural areas or places with limited abortion access. The bill essentially represents Congress trying to override the FDA's medical judgment about how safely this drug can be distributed, using its power over federal funding to enforce that decision.

To nullify modifications made by the Food and Drug Administration on January 3, 2023, to the risk evaluation and mitigation strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1) for mifepristone, and for other purposes.